Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study

医学 肝细胞癌 倾向得分匹配 内科学 胃肠病学 阶段(地层学) 回顾性队列研究 总体生存率 队列 完全响应 肝癌 存活率 肝切除术 外科 切除术 化疗 生物 古生物学
作者
Zili Hu,Xiaohui Wang,Yizhen Fu,Dinghua Yang,Zhongguo Zhou,Minshan Chen,Xin Song,Yaojun Zhang
出处
期刊:International Journal of Surgery [Wolters Kluwer]
卷期号:110 (2): 1019-1027 被引量:3
标识
DOI:10.1097/js9.0000000000000942
摘要

Background: High rate of tumor recurrence jeopardized the long-term survival of hepatocellular carcinoma (HCC) patients with complete response to transarterial chemoembolization (TACE). This study aims to evaluate the survival benefit of liver resection (LR) following the complete response to TACE for intermediate-stage HCC. Methods: A total of 281 intermediate-stage HCC patients with complete response to TACE followed by persistent observation (TACE group) or LR (TLR group) from 01 January 2011 to 31 December 2021 from three institutions in China were included. Overall survival (OS) and disease-free survival (DFS) of patients were compared between the two groups by propensity score–matching (PSM). Results: After PSM, the 1-year, 3-year, and 5-year OS rates were 91.4, 71.5, and 57.1% in the TACE group, and 96.6, 81.8, and 72.1% in the TLR group. The 1-year, 3-year, and 5-year DFS rates were 50.6, 22.6, and 6.8% in the TACE group, and 77.3, 56.3, and 38.7% in the TLR group. Compared with the TACE group, the TLR group showed significantly longer OS (HR, 0.528; 95% CI: 0.315–0.887; P =0.014) and DFS (HR, 0.388; 95% CI: 0.260–0.580; P <0.001). In patients beyond up-to-seven criterion, no difference was observed with OS (HR, 0.708; 95% CI: 0.354–1.419; P =0.329). LR following the complete response to TACE was safety. Conclusions: This study suggests that intermediate-stage HCC patients could benefit from LR following the complete response to TACE, resulting in longer OS and DFS. In addition, patients beyond up-to-seven could not benefit from the LR treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王有闲发布了新的文献求助10
刚刚
CipherSage应助艺玲采纳,获得10
刚刚
1秒前
1秒前
3秒前
勤奋流沙完成签到 ,获得积分10
3秒前
3秒前
lili完成签到,获得积分10
4秒前
贪玩的元彤完成签到,获得积分10
4秒前
5秒前
xiao完成签到,获得积分10
5秒前
5秒前
5秒前
7秒前
7秒前
7秒前
金石为开完成签到,获得积分10
8秒前
8秒前
kyt666完成签到,获得积分20
9秒前
9秒前
dong应助晚来天欲雪采纳,获得10
10秒前
11秒前
12秒前
雨前知了完成签到,获得积分10
12秒前
艺玲发布了新的文献求助10
12秒前
12秒前
13秒前
15秒前
17秒前
Akim应助勤劳的音响采纳,获得10
17秒前
17秒前
yu完成签到 ,获得积分10
17秒前
PEI发布了新的文献求助10
17秒前
18秒前
18秒前
JamesPei应助思绪摸摸头采纳,获得10
18秒前
19秒前
19秒前
细胞疗法搬砖工完成签到,获得积分10
19秒前
量子星尘发布了新的文献求助10
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976177
求助须知:如何正确求助?哪些是违规求助? 3520366
关于积分的说明 11202745
捐赠科研通 3256847
什么是DOI,文献DOI怎么找? 1798509
邀请新用户注册赠送积分活动 877704
科研通“疑难数据库(出版商)”最低求助积分说明 806516